<DOC>
	<DOCNO>NCT01785771</DOCNO>
	<brief_summary>An 39-week plus extension , open-label study estimate reduction HbA1c patient initial HbA1c &gt; 10 % &lt; /=12 % treat ITCA 650 20 mcg/day 13 week follow ITCA 650 60 mcg/day 26 week plus optional 26-week extension continue treatment ITCA 650 60 mcg/day</brief_summary>
	<brief_title>A Study Evaluate ITCA 650 Treatment Type 2 Diabetes Patients With High Baseline HbA1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Men woman age 18 80 year type 2 diabetes On stable treatment regimen diet exercise alone combination stable &amp; optimal nearoptimal dose metformin , sulfonylurea , TZD combination drug HbA1c &gt; 10.0 % â‰¤12.0 % Prior treatment GLP1 receptor agonist History hypersensitivity exenatide liraglutide FPG &gt; 300 mg/dL History medullary thyroid cancer family personal history multiple endocrine neoplasia type 2 Taking DPP4 inhibitor , incretin mimetics , alpha glucosidase inhibitor , meglitinides insulin within last 3 month history pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>